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An exhaustive description of the molecular recognition mechanism
between a ligand and its biological target is of great value because
it provides the opportunity for an exogenous control of the related
process. Very often this aim can be pursued using high resolution
structures of the complex in combination with inexpensive compu-
tational protocols such as docking algorithms. Unfortunately, in
many other cases a number of factors, like protein flexibility or sol-
vent effects, increase the degree of complexity of ligand/protein
interaction and these standard techniques are no longer sufficient
to describe the binding event. We have experienced and tested
these limits in the present study in which we have developed and
revealed the mechanism of binding of a new series of potent inhi-
bitors of Adenosine Deaminase. We have first performed a large
number of docking calculations, which unfortunately failed to yield
reliable results due to the dynamical character of the enzyme and
the complex role of the solvent. Thus, we have stepped up the
computational strategy using a protocol based on metadynamics.
Our approach has allowed dealing with protein motion and solva-
tion during ligand binding and finally identifying the lowest en-
ergy binding modes of the most potent compound of the series,
4-decyl-pyrazolo[1,5-a]pyrimidin-7-one.
ADA ∣ well-tempered metadynamics ∣ ligand/protein docking ∣
path collective variables ∣ reweighting algorithm
Adenosine Deaminase (ADA) regulates the purine metabo-lism by catalyzing the irreversible hydrolysis of adenosine
to inosine and 2′-deoxyadenosine to 2′-deoxyinosine. Thus, this
enzyme plays a crucial role in many pathologies such as inflam-
mation, some types of cancer, and others which are strictly
connected to the physiological level of these nucleosides (1–5).
Despite great efforts in developing ADA inhibitors, only Pentos-
tatin is currently in clinical use (I in Fig. S1) (3). However, recent
progress has been reported by Terasaka et al. and by some of us
who have developed a new generation of nonnucleoside ADA
inhibitors (II, III, and IV in Fig. S1) (6–11). Unfortunately, the
understanding at molecular level of the ligand/ADA interaction is
hampered by the pronounced ability of the active site to accom-
modate different inhibitors and by the crucial role played by
water molecules during ligand binding. A rational drug design is
further complicated by the fact that in response to different in-
hibitors, ADA can assume either an open or a closed conforma-
tion by changing the position of the H3 α-helix (Thr57-Ala73).
The open conformation corresponds to the apo-form (PDB ID
code 3iar) and is preferred when a nonnucleoside inhibitor is
bound (12, 13). In this case, the active site presents a hydrophilic
subsite S0 and three hydrophobic subsites F0, F1, and F2 (Fig. 1A)
(13). The S0 subsite is defined by the structural gate formed by a
β-strand (Leu182-Asp185) and two leucine side chains attached
to the H3 α-helix while the F0 site is formed by the hydrophobic
side chains of the H3 α-helix. In the open form the H3 α-helix
assumes a conformation that exposes two additional hydrophobic
subsites in the upper part the helix, namely F1 and F2 (13). The
binding of a ground-state inhibitor, like the hydroxylated form
of adenosine (HDPR) (V in Fig. S1) (14), induces a conforma-
tional change that leads to the closed form. In this case, the gate
is closed, the F1 and F2 sites are no longer accessible and the
active site is composed only by S0 and F0 (Fig. 1B).
While the structural difference between the two conformations
is believed to be the result of binding to different inhibitors, the
specific details of the enzyme conformational changes are still un-
clear. For instance, Kinoshita, et al. (15) have recently reported
that the ground-state inhibitor EHNA (VI in Fig. S1), expected to
bind the closed form, has been cocrystallized rather surprisingly
in the open one. In fact, experimental evidences suggest that the
n-hexyl group of EHNA interacts with the narrow hydrophobic
entrance of the ADA active site destabilizing the closed form.
Another example of the difficulty of predicting a ligand binding
model comes from the inhibitor FR221647, which has also been
found to bind to the open conformation in spite of having been
designed as a binder of the closed form (12).
In this confusing scenario, a practical approach is to find a
lead compound with whatever strategy works (high-throughput
screening, ligand-based design etc.), understand at molecular
level the lead/protein recognition mechanism and finally, if neces-
sary, try to rationally improve the lead.
Fig. 1. Representation of ADA in the open (A) and closed form (B).
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Here we have carried out the first two steps in this strategy by
applying a combined experimental and theoretical approach.
First we discovered a new class of inhibitors combining a number
of functional groups that are present in many of the reported
inhibitors (Table 1). Among these new inhibitors, the most potent
is 4-decyl-pyrazolo[1,5-a]pyrimidin-7-one, here named 3b. In the
lack of further experimental information we performed an exten-
sive series of calculations aimed at understanding the ligand/
protein molecular recognition process. We first performed stan-
dard docking calculations, which are the most economical way of
obtaining molecular information on ligand/protein interaction.
Unfortunately, all the docking attempts failed due to the ADA
flexibility and the active role of the water molecules. Thus we
had to step up the computational strategy and use metadynamics
(16, 17). Metadynamics has already been applied with success to
difficult docking processes (18–20). After extensive calculations,
the binding mode of 3b has been understood revealing also the
important role played by protein motion and solvent during the
ligand binding. We are comforted in our conclusions by a number
of experimental data and the similarity of our binding mode with
that of other ADA inhibitors.
Results
Ligand-Based Design. Prompted by the promising results of the
4-aminopyrazolo[3,4-d]pyrimidine (APPs) series (compound III
in Fig. S1) as ADA inhibitors, recently identified by some of us
(9, 10), and using our synthetic expertise in the pyrazolopyrimi-
dines field, we decided to further investigate this scaffold. Thus by
modifying the heterocyclic ring, a new series of compounds bear-
ing a pyrazolo[1,5-a]pyrimidin-7-one system has been developed.
Our investigation started synthesizing compounds 3a–c, carrying
a n-nonyl, n-decyl and n-undecyl chain, respectively, in the posi-
tion 4 of the heterocyclic core. As we demonstrated in the APPs
series (9), a long, linear, and hydrophobic alkyl chain can interact
favorably with the enzyme active site. In fact, tested on the bovine
spleen ADA, compounds 3a–c have been found to potently inhi-
bit ADA, showing Ki values in the nanomolar range (Table 1).
Moreover, an activity trend similar to the parent APPs was
observed as the ranking of inhibitory potency being n ¼ 8 (3a)
<n ¼ 9 (3b) >n ¼ 10 (3c). In order to further investigate the role
of the 4-alkyl chain in the interaction with the active site of the
enzyme, derivatives 7 and 8, bearing bulkier and more rigid
groups at position 4, were likewise synthesised and tested. In 7
the two phenyl rings are connected through an amide linker while
in 8 the linker is an ureic residue. Both these functions are present
in other potent ADA inhibitors (7, 12). As summarized in Table 1,
neither 7 nor 8 showed any appreciable inhibitory activity, proving
that in the pyrazolo[1,5-a]pyrimidin-7-one series the preferred sub-
stitution pattern is represented by the flexible alkyl chain.
In order to rationalize these experimental data and to proceed
with a structure-based lead optimization, it was necessary to un-
derstand at molecular level the binding mechanism to ADA of
the most potent compound of the series, 3b. This aim was
achieved through an extensive computational study described
in details in the following paragraphs.
Molecular Docking Studies.We first performed a series of docking
simulations of 3b in the ADA active site using the AutoDock pro-
gram (vs. 4.0) (21, 22). Both the open and closed conformation
were explored applying different docking settings (see SI Text).
We verified that AutoDock correctly predicts the experimental
pose for EHNA and HDPR in their open and closed form, re-
spectively. The docking calculations of 3b in the ADA closed
form gave among others a highly populated cluster in which
3b binds similarly to the nucleoside inhibitor HDPR. This cluster
presents also the lowest energy solution. In this pose 3b coordi-
nates the zinc ion through the oxygen of the pyrimidinone ring
(see Fig. S2A). Similarly to HDPR, 3b H-bonds with Asp295
and Glu217 in the S0 site through the oxygen and nitrogen atoms.
On the other hand, the n-decyl chain only partially fills the region
which, in the case of HDPR, would be occupied by the ribose ring
and points towards the hydrophobic region formed by the Leu62
Phe65 and Leu105 residues at the F0 site.
At first glance this is a plausible result, however in the light of
recent experiments (15), which found the ground-state inhibitor
EHNA to bind the open form of ADA and not the closed one as
expected, and being this ligand, at variance from the other com-
pounds of its class, not directly involved in the coordination of
the metal, we decided to substantiate the proposed binding pose
with further experiments. Thus, we investigated the ability of 3b
to coordinate the zinc ion performing a number of UV spectro-
scopy measurements. The UV spectra were recorded upon addi-
tion of increasing amount of zinc(II) ion into a homogeneous
solution of compound 3b (see SI Text). Surprisingly, no appreci-
able change in optical density of the absorption was observed,
thus indicating that 3b is not able to coordinate the metal.
This experimental result lead us to carry out additional dock-
ing calculations using a water molecule as the fifth coordination
group of zinc. The open form of ADA was used in all these
attempts and furthermore, some water molecules known to be
important for ligand binding, such as those involved in the inter-
actions of EHNA with Gly184 and Glu217 (15), were also expli-
citly taken into account in some of the docking calculations.
Unfortunately, in all these docking attempts, the ligand has never
been found to interact with residues known to be important for
ligand binding in ADA, such as Asp19, Gly184, and Glu217.
Furthermore, none of the water molecules, when included in
the docking calculation, has been involved in the ligand binding.
These reasons and the poor convergence of the docking calcula-
tions have casted doubts on the reliability of these results (see SI
Text for details).
We ascribe this failure to the fact that docking algorithms take
into account enzyme flexibility and solvent effects in a limited
way. In particular, the solvent can be taken into account either in
an implicit way or by adding, as done here, an appropriate num-
ber of explicit water molecules. However, the position of these
waters does not change during the calculations and if it is not
known beforehand, one risks to make things worse. In the ADA
case, while the position of the water coordinating the zinc ion can
be defined with a good level of precision, the other water mole-
cules, like those involved in the binding of some of the ADA in-
hibitors (14, 15, 23), can occupy different positions and assume a
number of orientations in response to different inhibitors. Thus,
the inclusion of waters through an explicit but fixed model might
Table 1. ADA Inhibition Data of Derivatives 3a–c, and 6–8
N° n R Ki (nM) *
3a 8 27.00 ± 0.95
3b 9 1.49 ± 0.03
3c 10 3.12 ± 0.09
6 NH2 n.a.
†
7 NHCOC6H4pCF3 n.a.
8 NHCONHC6H4pCF3 n.a.
(+)-EHNA 1.14 ± 0.10
*The Ki values are means SEM (standard error of the mean).
†n.a.: non active. Inhibition occurred at a concentration higher than 10 μM.
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be not helpful and could lead to rather inaccurate results as we
found to be the case here.
Well-Tempered Metadynamics. The failure of the docking calcula-
tions suggests using atomistic simulations in explicit water in or-
der to fully include solvent and protein flexibility. Unfortunately,
standard molecular dynamics (MD) can access only a time scale
of hundreds of nanoseconds, while processes like ligand/protein
docking usually take from microseconds to hundreds of seconds.
Thus, the use of enhanced sampling is mandatory. Among the
emerging techniques, metadynamics has shown to be useful in
the study of ligand docking (18–20). We used here this technique
in its new variant named well-tempered metadynamics, which en-
hances sampling allowing the reconstruction of the free-energy
profile of the process of interest by adding an adaptive bias on
a selected numbers of collective variables (CVs) (17). The choice
of CVs represents a crucial point because, to construct the Free-
Energy Surface (FES), the CVs must describe all the slow modes
relevant for the process under study (24–26).
The change from closed to open form is mostly determined by
the movement of the H3 α-helix and because it represents a slow
mode, use of a CV that is able to describe this movement is ne-
cessary (seeMethods for details). Recently, a number of path CVs
(PCV) have been developed in our research group (27, 28), which
are able to reconstruct the lowest free-energy path that connects
an initial and a final state. In the ADA case, assuming that the
initial and the final state correspond to ADA with the H3 α-helix
in the closed and open conformation, respectively, a PCV is con-
structed with the cartesian coordinates of the alpha carbons of
the residues that determine the α-helix movement. This type of
CV has been successfully applied in recent studies on complex
protein motion (29, 30) and ligand/protein docking (20).
In order to specify the position of the ligand relative to the
enzyme, we used a distance CV which measures the distance be-
tween the center of mass of the pyrazolo[1,5-a]pyrimidin-7-one
ring and that of a group of protein atoms (see Table S1).
Under the acceleration of metadynamics, the ligand is able to
explore the whole binding site moving from one free-energy mini-
mum to the next and then going back into the previous one, thus
overcoming the large free-energy barriers which are encountered
during the binding process. Thanks to these recrossings between
different basins, the calculated FES is accurate and quantitatively
well characterized with the deepest basin corresponding to the
preferred binding mode of the ligand inside the protein. We un-
derline once more that side chain flexibility, the motion of the H3
α-helix, and solvation are fully taken into account. It is essential
for the convergence of the calculations the use of the PCV which
accelerates the H3 α-helix motion, allowing a continuos change
from one conformation to the other.
The Energy Minima. The full exploration of the binding site took
approximately the equivalent of 0.3 μs. In Fig. 2 three different
minima, A, B, and C, can be identified. Basin A is approximately
3 kcal∕mol deeper than the other two minima. Here, the ligand is
into the innermost binding site while in B and C it is located in
more external sites. A detailed discussion on basin B and C is
given in the SI Text while the movie showing the ADA binding
site exploration by the ligand can be found as Movie S1.
Basin A. In this basin just as in the case of the EHNA/ADA com-
plex, the protein is in the open conformation (Fig. 3A). Here, the
ligand engages a number of favorable interactions with the sur-
rounding residues. In particular, the oxygen atom of the pyrazolo
[1,5-a]pyrimidin-7-one H-bonds to the NH backbone and the hy-
droxyl group of Ser103, while the nitrogen atom of the pyrazole
ring interacts with the Cys153 side chain (Fig. 2). Additionally,
the oxygen of the pyrimidinone moiety is involved in a H-bond
interaction with Asp19 via a water molecule. Besides these polar
interactions, the pyrazolo[1,5-a]pyrimidin-7-one ring engages
several hydrophobic contacts with the surrounding residues. In
fact, the methyl group of the pyrimidinone moiety points towards
the hydrophobic side chains of Phe65 and Met69, while the
aromatic ring lies close to His17 and His214 where a π-π and
a T-shaped interaction, respectively, are possible.
The atoms of the n-decyl chain were not used in defining the
distance CV (see Table S1) thus different conformations of this
flexible chain are to be found in the FES minima. After clustering
the ligand tail conformations, two main families have been found.
In one, Aa, the tail is placed in the hydrophobic F0 subsite where
multiple contacts are possible with residues such as Phe61,
Leu62, Phe65, Leu106, Trp117, Met155, Pro116, and His157. In
the other, Ab, the n-decyl chain points towards the upper part of
the H3 α-helix filling the F1 and F2 sites where different hydro-
phobic contacts are engaged with residues like Phe61, Leu58, and
Thr269 (see Fig. S3 A and B). In both cases the pyrazolo[1,5-a]
pyrimidin-7-one ring is always placed in the same position in the
active site and because the protein assumes always the open con-
formation, the alkyl tail can occupy all these hydrophobic pock-
Fig. 2. Representation of the FES of the 3b binding process
to ADA with the three main minima shown as insets, (A, B
and C). The FES is represented as function of the distance
and dihedral CVs using isosurfaces of 1 kcal∕mol. It is impor-
tant to underline that no bias has been added to the dihe-
dral CV and the statistics collected during the metadynamics
simulations on the torsion CV is used to generate the final
FES using the reweighting protocol (31). In the insets the li-
gand and the main interacting residues are displayed as li-
corice while the protein is represented as cartoon with the
H3 α-helix colored in yellow. The ligand/Asp19 water bridge
interaction is also shown while only polar hydrogens inter-
acting with the ligand are displayed for clarity.
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ets. Due to the high flexibility of this long alkyl chain, it is natural
to hypothesize that Aa and Ab are equally energetically favorable
although the one with the alkyl chain placed at the bottom of the
H3 α-helix, Aa (Fig. S3A), seems to be more probable as a con-
sequence of the higher hydrophobicity of this region. The relative
stability of these two different conformations has been further
studied and discussed in details in the following paragraph.
The Alkyl Tail. In order to assess the stability of the two binding
conformations Aa and Ab found at basin A, one with the alkyl
chain pointing towards the F0 site and the other one to the F1 and
F2 sites, respectively, MD simulations over 10 ns long have been
performed. The results showed a different behavior in the two
cases. The binding conformation Aa was very stable during the
whole simulation with a low average rmsd value for the ligand
(see Fig. S3C) and with all the above described ligand/protein
interactions fully conserved. In contrast, Ab first maintains its ori-
ginal position in the binding site but, after approximately 3.5 ns of
simulation, it moves the alkyl tail down along the H3 α-helix
transforming in Aa (see the lower graph in Fig. S3C).
The different behaviors of Aa and Ab observed during the MD
simulations prompted us to study in more detail the stability of
these two conformations. Thus, we performed a new metady-
namics run using as CV a distance that is able to distinguish the
two tail conformations (see Table S1). Once the calculations
converged, the FES was calculated along this CV (CV2) and the
distance CV used in the previous metadynamics simulations
(CV1) (see Fig. S3D) using the reweighting algorithm very re-
cently developed in our group by Bonomi, et al. (31). Thanks
to this algorithm, once the free energy of the metadynamics
simulation is converged, the FES can be recalculated on CVs
different from those used originally in the metadynamics run. The
FES shows two minima corresponding to Aa and Ab with the Aa
basin wider and about 1.3 kcal∕mol deeper than that of Ab. In
line with the MD study, these results suggest that although both
the poses are possible, Aa has a greater stability.
The Solvent Role. In the binding mode that characterizes basin A, a
water molecule plays a relevant role in the interaction between 3b
and Asp19 highlighting the importance of the solvent in ligand
binding. In order to assess the relevance of this water bridge in-
teraction, the FES along the distance and the interfacial water
CV (see SI Text) (32) has been calculated using the reweighting
protocol (31). Looking at the FES in Fig. 4, it is worth noting that
the ligand/ADA complex in basin A, corresponding approxi-
mately to the distance CV range of 7–8 Å, is always characterized
by the presence of at least one interfacial water between the
ligand and Asp19 and that the energetic contribution of this water
bridge interaction to the ligand binding is about 6 kcal∕mol
(Fig. 4). This is evidence of the important role of water similarly
to what has been found in other ADA inhibitors like EHNA or
HDPR (14, 15). A water at similar position but not interacting
directly with the ligand can be seen also in the X-ray structure
of EHNA/ADA complex (15). Our results suggest that this water
has a more than structural role. If in a docking calculation we now
include explicitly this water and orient the Asp19 side chain so as
to interact with 3b via this water, AutoDock predicts conforma-
tions very similar to that found by metadynamics among the most
favorable poses (see Fig. S4A).
The Asp19 residue is involved also in the binding of other
classes of inhibitors. This interaction occurs either through a direct
H-bond, like in the case of HDPR (PDB ID code 1krm) (14), or
via a water bridge interaction as in Coformycin (PDB ID code
3ewc) (23). Furthermore, it is worth mentioning that Kinoshita
et al. have suggested that the interactions of EHNA with His17
and Asp19 are anchor points for correctly placing the inhibitor
in the active site (15). As described above, both these residues play
a role in the 3b binding mode. We stress that none of this informa-
tion was used in setting up the simulation protocol.
Experimental Data Rationalization. Our results rationalize the ex-
perimental data on the pyrazolo[1,5-a]pyrimidin-7-one series
(Table 1), which show that the activities of 3a and 3c are lower
than that of 3b. We believe that neither 3a nor 3c can fill com-
fortably the F0 site, the one because the alkyl tail is too short, the
other because it is too long. We plan to perform further experi-
ments to validate our hypothesis. For the time being we limit our-
selves to docking calculations using the protein conformation
found by metadynamics and taking explicitly into account the
bridging water.
For 3b AutoDock finds that the pose predicted by meta-
dynamics is among the best scoring ones (see Fig. S4A). Note that
the docking algorithm did not find the Ab conformation suggest-
ing once more that the preferred and most stable binding confor-
mation is Aa.
In the case of 3a and 3c, docking calculations yielded different
results. In fact, docking of 3a showed a number of different bind-
ing possibilities and only in the second most populated cluster can
be found a pose comparable to that of 3b. However, in this pose
the pyrazolo[1,5-a]pyrimidin-7-one ring is translated and rotated
by 180 ° thus losing some favorable interactions with ADA (see
Fig. S4B). In contrast, docking on 3c found a binding mode very
similar to that of 3b with the pyrazolo[1,5-a]pyrimidin-7-one ring
slightly displaced from its usual position but still able to form all
the main interactions with the protein (see Fig. S4C). These re-
sults clearly validate our hypothesis that due to the loss or the
weakening of some favorable interactions with the protein a
Fig. 3. (A) Overlapping of the conformations of ADA found bymetadynamics
in basin A (yellow), ADA complexed with EHNA (green, PDB ID code 2z7g) (15)
and ADA complexed with HDPR (orange, PDB ID code 1krm) (14). The meta-
dynamics ADA conformation (yellow) is similar to that ligated to EHNA (open
form, green) with a low rmsd value of 1.84Å calculated for the H3 α-helix back-
bone atoms. (B) Overlapping in the ADA binding site of the 3b binding con-
formation calculated by metadynamics (cyan) and the X-ray binding
conformation of FR104783 (orange) (PDB ID code 1wxy) (13).
Fig. 4. Representation of the FES of the 3b/ADA binding process as function
of the distance and the interfacial water CVs using isosurfaces of 1 kcal∕mol.
Looking at the FES it is clear that when the ligand is in basin A (distance CV
range of 7–8 Å) at least one water bridge interaction is present between 3b
and Asp19 as shown in the inset picture. The energetic contribution to the
ligand binding of this interaction is about 5.6 kcal∕mol. This is computed as
the free-energy difference between the states when the water bridge inter-
action is present (Interfacial Water CV > 1) and those when this interaction is
not formed (Interfacial Water CV < 0.2), considering the ligand in basin A
(distance CV range of 7–8 Å).
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shorter alkyl chain (3a) affects the ADA affinity more than the
longer one (3c) in line with the experimental data.
Comparison with Other ADA Inhibitors. Comparing the binding
modes of different ADA inhibitors can be problematic because
this enzyme is very complex and similar ligands can bind to the
protein in different manners. Still we have found it useful to com-
pare the 3b binding mode with the FR104783 (VII in Fig. S1)
X-ray pose (PDB ID code 1wxy) (13). As can be seen in Fig. 3B,
there is a clear similitude, in fact one of the two phenol rings of
FR104783 occupies the bottom of the S0 site just like the pyra-
zolo[1,5-a]pyrimidin-7-one ring of 3b, and in both cases they are
H-bonded to Asp19. Furthermore, in FR104783, the second phe-
nol ring occupies the hydrophobic F0 subsite just like the alkyl tail
of 3b. The alkyloxy branch of FR104783 occupies the F1 and F2
subsites in a manner similar to the Ab pose of 3b suggesting the
utility of targeting this region in future lead optimization studies.
Other findings are further validated by a comparison with
other crystallographic structures. For instance, the open confor-
mation assumed by the protein when 3b is in the basin A is similar,
albeit slightly more open, to what has been found in the EHNA/
ADA complex (Fig. 3A) (15). Based on the metadynamics results,
we can a posteriori say that the failure of all the preliminary dock-
ing trials in which we used the open form of ADA either hydrated
(with three water molecules) or dry, is due to: (i) a slightly dif-
ferent conformation of the H3 α-helix; (ii) the flexibility of the
side chains which allows different ligands to bind; and (iii) the
user defined choice of water molecules to be considered in the
calculation. As we have seen in our docking samplings, the latter
choice is difficult and without a priori knowing the position
occupied by the waters, one can easily incur into errors.
Validation of the Method. The success of the metadynamics simu-
lations is strongly related to the choice of the CVs and when a
relevant CV is neglected the reconstruction of the FES fails
(20, 33). This implies the necessity of running a number of me-
tadynamics simulations to find out which CVs are needed for the
process under study. With the aim of assessing the reproducibility
of our results, we have carried out two additional metadynamics
simulations using CVs different from the original one (see SI Text,
Table S1, Fig. S5). The results have indicated that the H3 α-helix
motion (PCV) and the ligand move (distance CV) are the most
relevant degrees of freedom acting on the system and that the
inclusion of other CVs, like the interfacial water CV, is not
necessary to achieve the final results. Without knowing a priori
which are the most important degrees of freedom in a ligand/pro-
tein docking study, it is advisable to use standard CVs, such as
distance or torsion CVs, to achieve the best results in the shortest
time. Eventually, as we have shown in the Solvent Role paragraph,
one can construct, using the reweighting algorithm, the FES as
a function of different CVs thus investigating the role of these
degrees of freedom in the event under investigation. Another in-
triguing possibility is to use a very recently developed formalism,
namely orthogonal space random walk (34). This algorithm is
able to couple the CVs motion with the system dynamics through
structural relaxation, thus allowing the exploration of hidden
degrees of freedom. In doing so, CVs that are neglected during
the docking study, such as protein motion or solvent effect, can be
taken into account. This algorithm has been already used to sam-
ple small protein motion (35) and it would be interesting to apply
it in more complex studies such as ligand/protein docking.
Discussion
As discussed by Leach, et al. (36), docking methodologies seem to
have reached a plateau in recent years and are waiting for an
important breakthrough. In this study on a series of novel ADA
inhibitors we have been confronted with some of the major dock-
ing hurdles and overcome them through the use of an advanced
computational technique. Particularly, a metadynamics-based pro-
tocol has been employed to unveil the binding pose of the most
potent compound of the series 3b, taking into account effects such
as protein flexibility and solvation whose inaccurate description
renders docking not reliable. Our findings are in agreement with
a number of experimental data and supported by extensive calcu-
lations. Among the encouraging experimental facts wemention the
similitude of the 3b binding mode with the X-ray docking pattern
of other ADA inhibitors. Furthermore, the solvent has been found
to play a fundamental role in the binding of our inhibitor. In fact, a
water molecule mediates the important ligand interaction with
Asp19, that is known to be involved in the binding of many other
potent ADA inhibitors.
Certainly in terms of speed and computational cost, docking
protocols remain the first choice technique in lead discovery
and optimization, nevertheless in some cases, like ADA, the use
of more advanced techniques is necessary. Unfortunately, meta-
dynamics-based protocols are computationally expensive and are
not applicable for high-throughput screening purposes. For in-
stance, in the present case, considering only the final 3b/protein
docking metadynamics, the calculation required about 105 CPU
hours on High Performance Computing cluster, thus being fea-
sible if performed on just a few ligands. However, the high scal-
ability of molecular dynamics simulation codes and the increasing
computational power can help to achieve results in more reason-
able time.
The information derived from this study will be very useful for
the following lead optimization strategies. In fact, a low inhibitory
activity, nanomolar or picomolar, is a prerequisite to achieve
potent enzymatic inhibition and to develop drug candidates.
However, as very recently discussed by Gleeson, et al. (37), the
level of activity of molecules is not the only determining factor to
achieve drug efficacy because even other properties of molecules
(e.g., log P, pharmacokinetics profile) play crucial roles. Our re-
sults provide the possibility to rationally optimize the potent lead
compound 3b, representing an important opportunity to improve
the protein/ligand interaction and the pharmacokinetics proper-
ties of the new designed compounds.
Methods
Metadynamics Simulations. Before doing metadynamics simulations the 3b/
ADA complex was equilibrated through 5 ns MD under NPT conditions at
1 atm and 300 K using the parmff99SB Amber force field (38, 39), as imple-
mented in version 2.7 of the NAMD code (40). For the zinc subsite the bound
model was used adding to the force field the bond and angle parameters
reported by Coi, et al. (41). The Amber charges were applied to all the protein
and waters atoms except for the ligand and the zinc subsite. For these the
restrained electrostatic potential (RESP) charges were used (see SI Text). All
the simulations were carried out in explicit solvent using the TIP3P water
model (42) using periodic boundary conditions. The PLUMED plugin was used
to carry out metadynamics calculations with the NAMD code (43).
It is important to underline that because the ligand starting conformation
does not affect the final results of a well converged metadynamics simula-
tion, we can arbitrarily decide to use one of the poses predicted by the dock-
ing program. In our case, a pose from the most populated cluster in an open
form docking run was taken as the starting conformation.
The estimation Fðs;tÞ at time t of the free-energy surfaces FðsÞ as a func-
tion of the CV s was determined by metadynamics (15) in its new well-tem-
pered variant (16), using the following formula:
Fðs;tÞ ¼ −T þ ΔT
ΔT
V ðs;tÞ;
where Vðs;tÞ is the bias potential added to the system and T is the tempera-
ture of the simulation. ΔT is the difference between the fictitious tempera-
ture of the CV and the temperature of the simulation. The bias potential is
made up by the sum of the Gaussians deposited along the trajectories of the
CVs. Thanks to this new formalism, one can increase barrier crossing and
facilitate the exploration in the CVs space by tuning ΔT . A Gaussians deposi-
tion rate of 0.5 kcal∕mol per picosecond was initially used and gradually de-
creased on the basis of the adaptive bias with a ΔT of 3,300 K.
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The Path Collective Variables. In order to simulate the movement of the H3
α-helix, we used the path CV (PCV) (27) using as metrics the rmsd of the
Cα atoms of residues from Ile50 to Pro70. The PCVs are extremely powerful
whenever one wants to study a transition between two states A and B. As
state A we chose the X-ray conformation of ADA in the closed state (PDB
ID code 1krm) (14), while state B represents the open form (PDB ID code
2z7g) (15). Now, let SðRÞ be a reduced representation of a generic configura-
tion R. If the choice of S is appropriate, we would expect the reactive trajec-
tories to be bundled in a narrow tube around the path. To trace this path, we
follow the procedure of Branduardi et al. introducing the two variables sðRÞ
and zðRÞ:
sðRÞ ¼ 1
P − 1
∑
p
l¼1ðl − 1Þe
−λjjSðRÞ−SðlÞjj2
∑
p
l¼1 e
−λjjSðRÞ−SðlÞjj2 ;
zðRÞ ¼ − 1
λ
ln

∑
p
l¼1
e−λjjSðRÞ−SðlÞjj2

;
which measure the intercept and the distance of a microscopic configuration
R from the reference path SðlÞ, respectively. P is the number of frames that
define SðlÞ, jjSðRÞ—SðlÞjj is calculated as the rmsd and λ is proportional to the
inverse of the mean square displacement between successive frames. As the
structure of the H3 α-helix has only slight differences between the open and
closed conformation, we described the transition between the closed and
open conformation of the enzyme only using two frames Sð1Þ and Sð2Þ, being
the closed (state A) and the open conformation (state B), respectively. The λ
value was set to 0.75 Å-2. We performed metadynamics only in the space of
sðRÞ while zðRÞ was constrained to zðRÞ < 2Å2. This choice gives the possibility
for the system to explore conformations different from the reference states,
avoiding at the same time the loss of the alpha helical secondary structure.
In addition to sðRÞ, we have also used a distance and, in some meta-
dynamics runs, a torsion CV to describe the different conformations of the
ligand during the simulations (see Table S1).
Additional Materials and Methods information is given in the SI Text and
in Table S2, Table S3, and Table S4.
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Additional Docking Trials.Once the docking in the Adenosine Dea-
minase (ADA) closed form was seen to fail in providing any
convincing result we performed a number of extra docking simu-
lations in the ADA open form using as protein coordinates the
EHNA/ADA complex (PDB ID code 2z7g) (4). Unfortunately,
the docking calculations did not yield any reasonable result. In
fact, the two poses, one with the lowest binding score and the
other belonging to the most populated cluster, do not place the
ligand in the catalytic site but in more external solvent exposed
regions. Particularly, the best scoring pose occupies the upper
part of the H3 α-helix H-bonding with the backbone NH of
Leu58 and engaging a number of hydrophobic contacts with the
side chains of Leu58, Phe61, Thr187, and Thr269 (Fig. S2B). Si-
milarly to the best scoring pose, also in the most frequent one the
ligand is placed far from the catalytic site making polar contacts
in the external part of the enzyme with the His157 and Gln158
side chains and hydrophobic contacts with Phe65 (Fig. S2C). The
fact that in none of the docking solutions 3b interacts with resi-
dues like Asp19, Gly184, and Glu217, involved in the binding of
other ADA inhibitors, and the low convergence of the docking
calculations has casted doubts on the reliability of these results.
Therefore, once again further docking runs were carried out.
This time three water molecules, that mediate the interaction of
EHNA with Gly184 and Glu217, were included in the protein
structure. This choice was done because in our opinion the omis-
sion of these functional waters in the previous calculations could
be at the basis of the failure. The best ranked conformation and
the pose representing the most populated cluster occupies simi-
larly the ADA binding site (Fig. S2 D and E). In fact, the former
presents the pyrazolo[1,5-a]pyrimidin-7-one ring involved in H-
bonds with the His157 side chain and the backbone NH of
Asp185, while the alkyl tail points towards residues such as Phe61
and Phe65. On the other hand, the most occurred pose shows the
pyrazolo[1,5-a]pyrimidin-7-one ring H-bonding with the His157
and Gln158 side chains and the n-decyl chain pointing the inner
part of the enzyme where hydrophobic interactions with Phe65
are possible. Even in this last attempt, the ligand has never been
found to interact with residues known to be important for ligand
binding and furthermore, none of the water molecules, explicitly
included in the docking calculation, has been involved in the li-
gand binding suggesting us to discard also these solutions.
The Energy Minimum Basins B and C Found by Metadynamics. Basin B.
This minimum is approximately 3.1 kcal∕mol higher than basin A
(see Fig. 2 in the main text). In this pose the pyrazolo[1,5-a]pyr-
imidin-7-one ring is placed very close to the zinc ion although a
coordination of the metal is not possible due to the presence of
the zinc coordinating water. At this site only a T-shaped interac-
tion with His17 and a H-bond with Cys147 are possible, while all
the other interactions of the nucleotide-like ring described in
pose A are lost. In this minimum the enzyme has been found in
the open form which allows the ligand alkyl tail to engage
hydrophobic contacts with residues present in the upper part of
the H3 α-helix like Leu58, Phe61 and Leu62. The higher energy
value of basin B and the smaller number of interactions at this site
suggest to consider B as an intermediate pose of the ligand during
the binding process.
Basin C. The energy minimum C (see Fig. 2 in the main text) is
energetically comparable to B. At variance from A and B, here
the pyrazolo[1,5-a]pyrimidin-7-one ring is located in the external
part of the enzyme while the alkyl chain points towards the active
site. The O-7 of the pyrazolo[1,5-a]pyrimidin-7-one ring H-bonds
with the Ser103 side chain and a water molecule, while the N-1
interacts via a water bridge interaction with Asp19. Also in this
case ADA has been found in the open conformation and while
the C1′, C2′, C3′, and C4′ atoms of the ligand tail interacts with
Phe61, Leu62 and Phe65, the rest of the chain points deep in the
active site interacting with His17, Arg101, Cys153, and Ala183. It
is interesting to note that this binding conformation is similar to
some of those predicted by AutoDock when the ADA open form
is used. Actually, in the poses predicted by AutoDock the pyra-
zolo[1,5-a]pyrimidin-7-one ring visits an even more external part
of the enzyme, however, the overall volume occupied by 3b in the
catalytic site is almost the same. Basin C is 3.3 kcal∕mol higher
than the deepest minimum A suggesting a good stability of this
pose. The external position of this pose in the active site leads
us to suppose that C might represent a presite for the entry or
the exit of the ligand from the catalytic site.
Additional metadynamics simulations. Two extra metadynamics
simulations have been carried out to assess the results of the ori-
ginal metadynamics run. In the first one, a distance and a torsion
collective variable (CV) (Table S1) have been used with no path
CV (PCV) applied to the system. In this run, while the minimum
A has been found, the basins B and C disappeared in the Free-
Energy Surface (FES) (Fig. S5B). Actually, the minimum A is
slightly shifted to higher distance CV values (Fig. S5) reflecting
slight differences in pose A between the two matadynamics runs.
In fact, in the simulation without the PCV the pyrazolo[1,5-a]pyr-
imidin-7-one ring cannot optimally interact with Asp19, Ser103
and Cys153. This is due to the fact that no PCV has been used
in this run thus not allowing to fully explore the protein flexibility.
Therefore these results have shown that the use of the PCV to
sample the protein flexibility is needed to find the correct binding
mode and to get an accurate estimation of the free energy. Con-
sequently, the subsequent metadynamics simulation has been car-
ried out using again the PCV. In order to assess the independency
of the results from the choice of the distance CV, this time a dis-
tance CV different from that of the original metadynamics has
been used (see Table S1). In order to facilitate the comparison of
the results of the different simulations, once the calculations con-
verged, the FES has been recalculated through the reweighting
algorithm (13) using the distance and the torsion CV used in
the original run (Fig. S5C). Looking at the FES, one deepest en-
ergy minimum is present, which has the same CVs values of A. In
fact, in this minimum the ligand interacts with the protein simi-
larly to what was found in the original metadynamics sampling.
Particularly, the pyrazolo[1,5-a]pyrimidin-7-one ring interacts di-
rectly with Ser103 and Cys153 and through a water molecule with
Asp19, while the n-decyl chain occupies the F0 subsite. It is inter-
esting to note that basin B and C are again present in the FES.
The similarities of these results with those of the original run un-
derlines that it is essential to include a CV describing the H3 α-
helix flexibility. Failing to do so allows only to reproduce some of
the FES features. If instead we explicitly use the PCV that de-
scribes the H3 α-helix motion then we find a good level of repro-
ducibility even if different ligand/protein distance CV is used.
Finally, the constant presence of A across all these calculations
highlights the reproducibility of our results despite the different
CVs setting used, thus supporting the reliability of our findings.
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Synthesis of pyrazolo[1,5-a]pyrimidinones. The target compounds
were prepared as outlined in the Fig. S6. Reaction of the com-
mercially available 3-aminopyrazole 1 with the suitable alkyl bro-
mide, in the presence of anhydrous K2CO3, gave a mixture of
different products, which were separated by flash chromatogha-
phy. The pure compounds were identified by analytical and spec-
tral data, proving that through reaction with both 1-bromononane
and 1-bromoundecane the desired N-alkyl-1H-pyrazol-3-amines
2a,c were obtained with the corresponding di-alkylated by pro-
ducts 2d,e, while by using 1-bromodecane the target N-decyl-
1H-pyrazol-3-amine 2b was obtained with its regioisomer 2f. Re-
action of 2a–c with ethyl-3-oxobutanoate gave the target pyrazolo
[1,5-a]pyrimidin-7-ones 3a–c and their regioisomers pyrazolo[1,5-
a]pyrimidin-5-ones 4a–c, which were separated by flash cromato-
graphy and characterized by spectral data. Alkylation of 3-ami-
nopyrazole 1 with 1-(chloromethyl)-4-nitrobenzene afforded a
mixture of mono and di-alkylated products, 2g–i, obtained pure
through flash chromatoghaphy. Cyclization of 2g with ethyl-3-ox-
obutanoate provided the target heterocycle 5. This latter was then
subjected to catalytic hydrogenation, performed under atmo-
spheric pressure and room temperature in the presence of Pd/
C, to obtain the key intermediate 4-(4-aminobenzyl)-5-methyl-
pyrazolo[1,5-a]pyrimidin-7(4H)-one 6. Reaction of 6 with 4-(tri-
fluoromethyl)benzoyl chloride, in the presence of triethylamine,
let to the inhibitor 7, while treatment with 1-isocyanato-4-(tri-
fluoromethyl)benzene gave the inhibitor 8. Both reactions were
conducted under microwave irradiation, which greatly enhanced
the speed of the reaction simplifying the experimental protocol.
Adenosine Deaminase inhibition assay. The in vitro activity of ADA
(type IX from bovine spleen, 150–200 U∕mg, Sigma) was deter-
mined spectrophotometrically by monitoring for 2 min at 262 nm
the decrease in absorbance resulting from deamination of adeno-
sine into inosine, catalyzed by the enzyme. The change in adeno-
sine concentration/min, in absence and in the presence of the
newly synthesized compounds, was determined using a Beckman
DU-64 kinetics software program (Solf Pack TMModule) follow-
ing a previously reported protocol (13).
Chemistry. Melting points were determined using a Reichert Kö-
fler hot-stage apparatus and are uncorrected. Infrared spectra
were recorded with a FT-IR spectrometer Nicolet/Avatar in Nujol
mulls. Routine 1H NMR spectra were recorded in DMSO-d6
solution on a Varian Gemini 200 spectrometer operating at
200 MHz. Evaporation was performed in vacuo (rotary evapora-
tor). Anhydrous sodium sulfate was always used as the drying agent.
Analytical TLC was carried out on Merck 0.2 mm precoated silica
gel aluminum sheets (60 F-254), with visualization by irradiation
with a UV lamp. Flash chromatography was performed with Merck
Silica gel 60 (230–400 mesh ASTM). The microwave-assisted pro-
cedures were carried out in sealed vessels using a CEM/Discover
LabMate 220 VAC∕50 Hz microwave system. Elemental analyses
were performed by our Analytical Laboratory and agreed with the-
oretical values to within 0.4%.
3-Aminopyrazole, 1-(chloromethyl)-4-nitrobenzene, ethyl-3-ox-
obutanoate, 4-(trifluoromethyl)benzoyl chloride, 1-isocyanato-4-
(trifluoromethyl)benzene and the alkyl bromides used to obtain
compounds 2a–c were from Sigma-Aldrich. All other chemicals
were of reagent grade.
General procedures for the synthesis of alkyl pyrazol-3-amines 2a–f.
The suitable alkyl bromide (12 mmol) was added drop wise to a
suspension of 3-aminopyrazole 1 (0.830 g, 10 mmol) and anhy-
drous potassium carbonate (1.66 g, 12 mmol) in 25 mL of
dimethylformamide (DMF), and the resulting mixture was stirred
at 80 °C until the disappearance of the starting material (TLC, 2–
3 h). After cooling, the inorganic material was filtered off and the
solution was evaporated to dryness under reduced pressure. The
crude obtained was flash chromatographed (eluting system: ethyl
acetate/cyclohexane 3∕7) to separate the target products 2a–c
from the undesired 2d–e. Each compound, obtained either as
a solid or as a pure oily product, was then characterized by ana-
lytical and spectral data (Table S2).
N-(4-nitrobenzyl)-pyrazol-3-amine 2 g, N,1-bis(4-nitrobenzyl)-pyrazol-
3-amine 2h. 1-(4-nitrobenzyl)-pyrazol-3-amine 2i. A solution of 1-
(chloromethyl)-4-nitrobenzene (2.05 g, 12 mmol) in DMF was
added drop wise to a suspension of 3-aminopyrazole 1 (0.830 g,
10 mmol) and anhydrous potassium carbonate (1.66 g, 12 mmol)
in 25 mL of DMF, and the resulting mixture was stirred at 50 °C
for 1 h. After cooling, the inorganic material was filtered off and
the solution was evaporated to dryness under reduced pressure.
The crude obtained was flash chromatographed (eluting system:
ethyl acetate/cyclohexane 5∕5) to separate the target product 2g
from the undesired 2h,i. Each compound was then recrystallized
from the appropriate solvent (Table S2).
General procedures for the synthesis of 4-alkyl-5-methylpyrazolo[1,5-
a]pyrimidin-7-ones 3a–c and 4-alkyl-7-methylpyrazolo[1,5-a]pyrimi-
din-5-ones 4a–c. A mixture of the suitable N-alkylpyrazol-3-amine
2a–c (1.00mmol) and ethyl-3-oxobutanoate (0.15mL, 1.20mmol)
was irradiated with microwaves at 140 °C for 20 min. The cooled
residue was diluted with ethyl acetate and flash chromatographed
(eluting system: ethyl acetate/cyclohexane 5∕5) to separate com-
pounds 3a–c from the isomers 4a–c. Each product was then re-
crystallized from the appropriate solvent (Table S3).
5-methyl-4-(4-nitrobenzyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 5. N-(4-
nitrobenzyl)-pyrazol-3-amine 2g (0.218 g, 1.00 mmol) and ethyl-
3-oxobutanoate (0.150 mL, 1.20 mmol) were mixed thoroughly
and irradiated with microwaves at 110 °C for 10 min. The cooled
residue was then diluted with toluene and the solid separated was
collected and recrystallized from the appropriate solvent
(Table S3).
5-methyl-4-(4-aminobenzyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 6. A
suspension of 5-methyl-4-(4-nitrobenzyl)pyrazolo[1,2-a]pyrimi-
din-7(4H)-one 5 (0.284 g, 1.00 mmol) and 10% Palladium on
Carbon (0.100 mmol) in 250 mL of absolute ethanol was hydro-
genated at atmospheric pressure and room temperature until the
theoretical uptake of hydrogen was achieved. After filtering the
catalyst, the solvent was evaporated to dryness to give a pale yel-
low solid which was collected and recrystallized from the appro-
priate solvent (Table S3).
N-(4-((5-methyl-7-oxopyrazolo[1,5-a]pyrimidin-4(7H)-yl)methyl)phe-
nyl)-4-(trifluoromethyl) benzamide 7. 5-Methyl-4-(4-aminobenzyl)
pyrazolo[1,5-a]pyrimidin-7(4H)-one 6 (0.254 g, 1.00 mmol), 4-
(trifluoromethyl)benzoyl chloride (0.178 mL, 1.20 mmol), and
triethylamine (0.167 mL, 1.20 mmol) were mixed thoroughly
and irradiated with microwaves at 140 °C for 10 min. The cooled
residue was then diluted with ice-water and the solid separated
was filtered and purified by recrystallization from the appropriate
solvent to give the target compound, 7 (Table S3).
1-(4-((5-methyl-7-oxopyrazolo[1,5-a]pyrimidin-4(7H)-yl)methyl)phe-
nyl)-3-(4-(trifluoromethyl)phenyl)urea 8. 5-Methyl-4-(4-aminoben-
zyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 6 (0.254 g, 1.00 mmol)
and 1-isocyanato-4-(trifluoromethyl)benzene (0.130 mL,
1.20 mmol) were mixed thoroughly and irradiated with micro-
waves at 140 °C for 10 min. The cooled residue was then diluted
with toluene and the solid separated was filtered and purified by
recrystallization from the appropriate solvent to give the target
compound, 8 (Table S3).
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UV absorption spectroscopic analyses. Stock solutions of 100.0 μM
ZnCl2, from Sigma-Aldrich, and of 50.00 μM 3b were prepared by
dissolving the required amount of substance in distilled water.
For 3b the solubility was facilitated by using DMSO. Metal co-
ordination experiments were carried out by adding from 0 to
2.0 mL of zinc(II) ion solution, in 0.5 mL increments, to
2.0 mL of 50.00 μM 3b and diluting to a total volume of 5.0 mL
with potassium phosphate pH ¼ 7.2. Titration was monitored by
UV-Vis spectroscopy measuring the absorbance of each solution,
at ranging from 190 to 260 nm and at T ¼ 20 °C, using a Perki-
nElmer Lambda 25 spectrophotometer.
Docking simulations.Molecular docking simulations of 3b, EHNA
and HDPR in the three-dimensional X-ray structures of ADA
were carried out using the AutoDock software package (version
4.0) (1, 2). The protein coordinates were taken from the HDPR/
ADA (PDB ID code 1krm) (3) and EHNA/ADA complex (PDB
ID code 2z7g) (4) for the closed and open form, respectively.
Ligands and protein setup. The charges on the ligand were com-
puted using the restrained electrostatic potential (RESP) fitting
procedure (5). First the ESP were calculated by means of the
Gaussian package (6) using a 6-31G* basis set at Hartree-Fock
level of theory and then the RESP charges were obtained by a
two-stages fitting procedure (7). The Gasteiger-Marsili partial
charges (8) were assigned to the protein atoms except for the zinc
ion and its coordinating residues (zinc subsite). These are repre-
sented by His12, His15, His211, Asp292 and a water molecule
when the ADA open form is considered and His12, His15,
His211, Asp292, and HDPR when the closed form is used. For
these atoms the RESP charges were obtained using the unrest-
ricted density functional UB3LYP. For the optimization and
the subsequent electrostatic potential (ESP) calculation, the fol-
lowing locally dense basis set was used: 6-31G* was assigned to
the Zn coordinating side chains, except those atoms directly in-
volved in the zinc coordination. In fact, to better describe charge
transfer phenomena, the basis set on these atoms was augmented
to 6–31+G*. Conversely, to limit the amount of computational
time, the other atoms of the coordinating residues, as well as the
acetyl (ACE) and N-methyl (NME) capping groups, were treated
with the smaller 3–21G* basis set. The Stuttgart-Dresden ECP
(SDD) was used for zinc ion.
The octahedral coordination geometry of the Zn ion for ab
initio calculations was obtained from crystallographic templates
(PDB ID code 2z7g and 1krm) and the zinc was considered in the
þ2 oxidation state with low spin state (S ¼ 0).
Hence, the system was geometrically optimized constraining
the backbone atoms, and using the previously reported locally
dense basis set. The model system was then optimized till reach-
ing the default Gaussian03 convergence criterion.
The RESP charges were then calculated on the geometrically
minimized Zn subsite. First the ESP were calculated again by
means of the Gaussian package (6) and then the RESP charges
were obtained by a two-stages fitting procedure (7), fitting first
the polar areas by using weak hyperbolic restraints (0.0005 a.u.),
and then fitting the remaining areas imposing equivalencies and by
using a stronger hyperbolic restraint (0.001 a.u.). In each step, the
charges of the standard residues ACE and NME were constrained
to their AMBER force field value (9). The electrostatic potential,
used as input by the program to compute the RESP charges, was
sampled according to the Merz-Singh-Kollman scheme (10, 11),
namely using 10 concentric layers at the default level of spacing,
a surface density of 6 points∕Å2, and adopting the covalent radius
of 0.88 Å for zinc as reported on the WebElements server (Winter
M.WebElements™ Periodic Table. United Kingdom: University of
Sheffield. http://www.webelements.com/). Hence, the computed
charges for ligands and Zn subsite were used for further computa-
tional calculations.
Docking setup. The docking area has been defined by a box, cen-
tered on the cartesian coordinates of the zinc ion. Grids points of
60 × 60 × 60 with 0.375 Å spacing were calculated around the
docking area for all the ligand atom types using AutoGrid4.
For each ligand, 100 separate docking calculations were per-
formed. Otherwise default docking parameters were applied.
The docking conformations were clustered on the basis of rmsd
(rmsd ¼ 1.5 Å) between the cartesian coordinates of the ligand
atoms and were ranked based on the AutoDock scoring function.
The interfacial water CV. In order to assess the contribution of the
water bridge interaction between compound 3b and Asp19 in the
binding process, we have reweighted (12) the free energy along
the distance and the interfacial water CV (14). This latter CV is
defined as:
sIntWat ¼∑
n0
i

1 − ðjri−r1jr0 Þn
1 − ðjri−r1jr0 Þm

1 − ðjri−r2 jr0 Þn
1 − ðjri−r2 jr0 Þm

;
where jri − r1j and jri − r2j are the distances between the n0
waters oxygens and the oxygen atom of the pyrazolo[1,5-a]pyri-
midin-7-one ring and one of the carboxylic oxygens of Asp19, re-
spectively, and r0 ¼ 4, n ¼ 6 and m ¼ 12 are the values used in
the switching function to simulate H-bond interaction.
The VMD program (15) was used for visualization and data
analysis while the figures were made using the PyMOL software
(16).
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Fig. S1. Some of the most potent ADA inhibitors: (I) deoxycoformycin (dCF or Pentostatin), (II) 1-((3R, 4S)-1-(2-(4-chlorophenyl)benzo[d]oxazol-4-yl)-4-hydro-
xypentan-3-yl)-1H-imidazole-4-carboxamide, (III) (R)-4-amino-2-(2-hydroxy-1-decyl)pyrazolo[3,4-d]pyrimidine, (IV) 1-(4-((4-oxo-4,5-dihydropyrazolo[3,4-d]pyr-
imidin-2-yl)methyl)phenyl)-3-(4-(trifluoromethyl)phenyl)urea, (V) (R)-6-hydroxy-1,6-dihydropurine ribonucleoside (HDPR), (VI) erythro-9-(2-hydroxy-3-nonyl)
adenine ((+)-EHNA), (VII) N-(4,5-bis(4-hydroxyphenyl)thiazol-2-yl)hexanamide (FR104783).
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Fig. S2. (A) Representation of the 3b binding conformation found by AutoDock in the closed form of ADA. (B) and (C) Representation of the 3b binding
conformations found by AutoDock in the ADA open formwhen awater molecule has been considered as the fifth coordinating group of the zinc ion. (B) Shows
the ligand conformation representing the best scored cluster while (C) that representing the most populated cluster. (D) and (E) Representation of the 3b
binding conformations found by AutoDock in the ADA open form when the zinc coordinating water and three additional water molecules are considered. As
reported in the main text the latter are involved in H-bond bridge interactions between EHNA and ADA (PDB ID code 2z7g). (D) Shows the ligand conformation
representing the best scored cluster while (E) that representing the most populated cluster. The ligand and the main interacting residues are displayed as
licorice while the protein is represented as cartoon with the H3 α-helices colored in yellow. Only heavy atoms are displayed for clarity.
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Fig. S3. Representation of the binding mode of the two ligand tail conformation families found by metadynamics. (A) Shows that with the n-decyl chain
interacting with the residues present at the bottom of the H3 α-helix (binding conformation Aa) while (B) that with the alkyl tail occupying the upper part of
the H3 α-helix (binding conformation Ab). The ligand and themain interacting residues are displayed as licorice while the protein is represented as cartoonwith
the H3 α-helix colored in yellow. The ligand/Asp19 water bridge interaction is also shown while only polar hydrogens interacting with the ligand are displayed
for clarity. (C) (Top graph) Plot of the rmsd of the heavy atoms of the pyrazolo[1,5-a]pyrimidin-7-one ring during over 10 ns ofMD simulations with the ligand in
the Aa binding conformation. The very low average rmsd value of 0.93 Å for the pyrazolo[1,5-a]pyrimidin-7-one ring reflects the good stability of this pose.
(Lower graph) Plot of the rmsd of the heavy atoms of the ligand in the binding conformation Aa (black lines) and Ab (red lines) during over 10 ns of standard
MD. The rmsd values are calculated relatively to the ligand coordinates in the Aa conformation at the beginning of the simulation. The red plots clearly show
that the Ab conformation changes in Aa after approximately 3.5 ns. This change is remarked also by the minimum rmsd value of 0.93 Å calculated for Ab
relative to Aa. (D) Representation of the FES of the ligand conformations in ADA as function of the new distance CV (CV2) and the distance CV used in the
original metadynamics simulations (CV1). Isosurfaces of 1 kcal∕mol is used. Looking at the FES two minima are found corresponding to the two ligand tail
conformations Aa and Ab. The Aa basin is wider and 1.3 kcal∕mol deeper than that of Ab with an energetic barrier Aa → Ab of approximately 3.5 kcal∕mol
between the two minima. These results are in line with the MD study that suggests a greater stability of the Aa conformation (Fig. S3C).
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Fig. S4. (A) Overlapping in the ADA binding site of the 3b binding conformations predicted by metadynamics (cyan) and by AutoDock (red). Using the ADA
conformation ligated to EHNA (PDB ID code 2z7g) this docking trial has been executed including the water molecule that mediates the interaction between the
ligand and Asp19 with the latter optimally oriented for such interaction. (B) and (C) Comparison of the biding mode of 3b (cyan) with those calculated by
AutoDock for 3a (b) and 3c (c). (B) If compared with 3b, 3a showed the pyrazolo[1,5-a]pyrimidin-7-one ring translated and rotated by 180° with the O7 atom
involved in a water bridge interaction with Asp19 and a H-bond with Cys153. Due to the ring rotation the hydrophobic interactions between the methyl group
of the pyrimidinonemoiety and Phe65 andMet69 are lost as well as the stacking interactions with His17 and His214. On the other hand, the new position of the
pyrazolo[1,5-a]pyrimidin-7-one ring in the active site allows the shorter n-nonyl chain to fill the F0 site in a way similar to the n-decyl chain in 3b. (C) In contrast,
3c presents a bindingmode very similar to that of 3bwith the pyrazolo[1,5-a]pyrimidin-7-one ring slightly displaced from its usual position but still able to form
all themain interactions with the protein. The ligand and themain interacting residues are displayed as licorice while the protein is represented as cartoonwith
the H3 α-helix colored in yellow. The ligand/Asp19 water bridge interaction is also shown while only polar hydrogens interacting with the ligand are displayed
for clarity.
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Fig. S5. Comparison between the FES graphs obtained using different CVs settings shown using isosurfaces of 1 kcal∕mol. Å. (A) FES obtained using the
distance and the PCV and reweighted on the torsion CV, (B) FES obtained using the distance, and torsion CV without using the path CV and (C) FES obtained
using a different distance CV and the PCV. In order to facilitate the comparison, in the latter case the FES is recalculated along the distance and torsion CVs used
in the original metadynamics. The basin A is constantly found through all the metadynamics simulations although this basin is less deep and slightly shifted
along the distance CV when no PCV is used (see graph B). Furthermore, basin B and C have not been found in the simulations without the PCV while they
reappear if a distance CV and the PCV are used. These results highlight the importance of simulating the ADA flexibility to properly define the interactions
engaged by the ligand with the protein along its binding path.
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Fig. S6. Synthesis of Pyrazolo[1,5-a]pyrimidinone Derivatives.
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Movie S1. The movie shows the exploration of the ADA binding site by the inhibitor 3b simulated through metadynamics calculations.
Movie S1 (MOV)
Table S1. List of atoms that define the different CVs used in the metadynamics
simulations
List of atoms used to define the distance and torsion CV. Distance CV is defined as the
distance between the center of mass of groups of atoms.
CV type Atom Group
Distance CMR * 1
Distance Val16Cα 2
Distance His17Cα 2
Distance Val100Cα 2
Distance Arg101Cα 2
Torsion Val16Cα -
Torsion Arg101Cα -
Torsion C1’ of the alkyl tail(attached to N4 of the pyrazolopyrimidinone ring) -
Torsion N1 of the pyrazolopyrimidinone ring -
List of atoms used to define the distance CV used in the metadynamics simulations to assess
the stability of Aa and Ab conformations. Distance CV is defined as the distance between
the center of mass of groups of atoms.
CV type Atom Group
Distance C7′ of the alkyl tail 1
Distance C8′ of the alkyl tail 1
Distance C9′ of the alkyl tail 1
Distance Ser265Cα 2
Distance Leu268Cα 2
List of atoms used to define the distance CV used in the extra metadynamics simulations.
Distance CV is defined as the distance between the center of mass of groups of atoms.
CV type Atom Group
Distance CMR * 1
Distance Val16Cα 2
Distance Asp295Cα 2
*CMR is the center of the mass of the ligand pyrazolo[1,5-a]pyrimidin-7-one ring
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Table S2. Physical properties and spectral data of compounds 2a–i
No. R1 R2 Yield
(%)
mp (°C) Recyst. solv.
*
Formula† IR (ν, cm−1) 1H-NMR (δ, ppm)
2a ðCH2Þ8CH3 H 71 oil C12H23N3 3,302; 3,216;
1,664; 1,557
0.86 (t, 3H, CH3); 1.15–1.32 (m, 12H, CH2);
1.47 (t, 2H, CH2); 2.96 (m, 2H, CH2);
4.99 (bs, 1H, NH, exc.); 5.39 (d, 1H, H4);
7.28 (d, 1H, H5); 11.44 (bs, 1H, NH, exc.)
2b ðCH2Þ9CH3 H 62 28–30 EtOH C13H25N3 3,313; 3,190;
1,552; 1,495
0.86 (t, 3H, CH3); 1.13–1.30 (m, 14H, CH2);
1.45 (t, 2H, CH2); 2.93 (m, 2H, CH2);
4.99 (bs, 1H, NH, exc.); 5.39 (d, 1H, H4);
7.28 (d, 1H, H5); 11.42 (bs, 1H, NH, exc.)
2c ðCH2Þ10CH3 H 63 32–34 EtOH C14H27N3 3,298; 3,206;
1,557; 1,495
0.85 (t, 3H, CH3); 1.14–1.31 (m, 16H, CH2);
1.44 (t, 2H, CH2); 2.93 (m, 2H, CH2);
4.96 (bs, 1H, NH, exc.); 5.38 (d, 1H, H4);
7.25 (d, 1H, H5); 11.43 (bs, 1H, NH, exc.)
2d ðCH2Þ8CH3 ðCH2Þ8CH3 15 oil C21H41N3 3,190; 1,552;
1,526; 1,495
0.85 (t, 6H, CH3); 1.11–1.38 (m, 24H, CH2);
1.43 (t, 2H, CH2); 1.61 (t, 2H, CH2); 3.06 (m, 2H, CH2);
3.81 (m, 2H, CH2); 4.99 (t, 1H, NH, exc.);
5.44 (d, 1H, H4); 7.28 (d, 1H, N5)
2e ðCH2Þ10CH3 ðCH2Þ10CH3 21 oil C25H49N3 3,262; 1,577;
1,557; 1,495
0.85 (t, 6H, CH3); 1.10–1.36 (m, 32H, CH2);
1.43 (t, 2H, CH2); 1.641 (t, 2H, CH2); 2.92 (m, 2H,
CH2);
3.80 (m, 2H, CH2); 4.91 (t, 1H, NH, exc.);
5.35 (d, 1H, H4); 7.29 (d, 1H, N5)
2f H ðCH2Þ9CH3 22 oil C13H25N3 3,329; 3,196;
1,716; 1,634
0.85 (t, 3H, CH3); 1.12–1.30 (m, 14H, CH2);
1.64 (t, 2H, CH2); 3.79 (m, 2H, CH2);
5.08 (bs, 2H, NH2, exc.); 5.22 (d, 1H, H4);
6.99 (d, 1H, H5)
2g CH2C6H4pNO2 H 62 118–
119
EtOH C10H10N4O2 3,443; 3,250;
1,591
4.35 (d, 2H, CH2);
5.45 (d, 1H, H4); 5.92 (t, 1H, NH, exc.);
7.31 (d, 1H, H5); 7.60 (d, 2H, ArH);
8.16 (d, 2H, ArH); 11.49 (bs, 1H, NH, exc.)
2h CH2C6H4pNO2CH2C6H4pNO2 21 250–
252
EtOH C17H15N5O4 3,325; 3,125;
1,649; 1,608
4.36 (d, 2H, CH2); 5.45 (d, 1H, H4);
5.34 (s, 2H, CH2); 5.92 (t, 1H, NH, exc.);
7.32 (d, 1H, H5); 7.44 (d, 2H, ArH);
7.62 (d, 2H, ArH); 7.81 (d, 2H, ArH);
8.17 (d, 2H, ArH)
2i H CH2C6H4pNO2 12 171–
173
EtOH C10H10N4O2 3,325; 3,125;
1,649; 1,608
5.27 (s, 1H, H4); 5.34 (s, 2H, CH2);
5.96 (bs, 2H, NH2, exc.); 7.31 (s, 1H, H5);
7.60 (d, 2H, ArH); 8.17 (d, 2H, ArH)
*Compounds 2a, d–f were obtained analytically pure through flash chromatography
†Elemental analyses for C, H, N were within 0.4% of the calculated values.
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Table S3. Physical properties and spectral data of compounds 3a–c, 4a–c, and 5–8
No. R Yield (%) Mp (°C) Recyst. solv. Formula IR (ν, cm-1) 1H-NMR (δ, ppm)
3a ðCH2Þ8CH3 46 63–65 EtOH C16H25N3O 1,685; 1,659;
1,557
0.85 (t, 3H, CH3); 1.10–1.29 (m, 12H, CH2);
1.69 (t, 2H, CH2); 2.41 (s, 3H, CH3);
4.02 (t, 2H, CH2); 5.73 (s, 1H, H6);
6.40 (d, 1H, H3); 7.89 (d, 1H, H2)
3b ðCH2Þ9CH3 45 64–66 EtOH C17H27N3O 1,690; 1,648;
1,562
0.86 (t, 3H, CH3); 1.11–1.29 (m, 14H, CH2);
1.69 (t, 2H, CH2); 2.42 (s, 3H, CH3);
4.02 (t, 2H, CH2); 5.74 (s, 1H, H6);
6.40 (d, 1H, H3); 7.89 (d, 1H, H2)
3c ðCH2Þ10CH3 49 76–78 EtOH C18H29N3O 1,690; 1,659;
1,552
0.86 (t, 3H, CH3); 1.10–1.30 (m, 16H, CH2);
1.68 (t, 2H, CH2); 2.41 (s, 3H, CH3);
4.02 (t, 2H, CH2); 5.73 (s, 1H, H6);
6.40 (d, 1H, H3); 7.89 (d, 1H, H2)
4a ðCH2Þ8CH3 35 43–45 EtOH C16H25N3O 1,680; 1,562 0.85 (t, 3H, CH3); 1.09–1.27 (m, 12H, CH2);
1.70 (t, 2H, CH2); 2.48 (s, 3H, CH3);
3.91 (t, 2H, CH2); 6.01 (s, 1H, H6);
6.22 (d, 1H, H3); 7.84 (d, 1H, H2)
4b ðCH2Þ9CH3 35 45–47 EtOH C17H27N3O 1,685; 1,560 0.85 (t, 3H, CH3); 1.11-1.29 (m, 14H, CH2);
1.69 (t, 2H, CH2); 2.49 (s, 3H, CH3);
3.94 (t, 2H, CH2); 6.01 (s, 1H, H6);
6.22 (d, 1H, H3); 7.84 (d, 1H, H2)
4c ðCH2Þ10CH3 30 54–56 EtOH C18H29N3O 1,682; 1,563 0.85 (t, 3H, CH3); 1.10–1.28 (m, 16H, CH2);
1.69 (t, 2H, CH2); 2.49 (s, 3H, CH3);
3.91 (t, 2H, CH2); 6.01 (s, 1H, H6);
6.22 (d, 1H, H3); 7.84 (d, 1H, H2)
5 NO2 82 275 dec. EtOH C14H12N4O3 1,741; 1,726;
1,691
2.33 (s, 3H, CH3); 5.53 (s, 2H, CH2); 5.86 (s, 1H, H6);
6.30 (d, 1H, H3); 7.42 (d, 2H, ArH);
7.85 (d, 1H, H2); 8.21 (d, 2H, ArH)
6 NH2 92 172–173 EtOH C14H14N4O 3,414; 3,342;
1,673
2.38 (s, 3H, CH3);
5.14 (bs, 4H, CH2, NH2); 5.78 (s, 1H, H6);
6.37 (d, 1H, H3); 6.52 (d, 2H, ArH);
6.86 (d, 2H, ArH); 7.86 (d, 1H, H2)
7 NHCOC6H4-p-CF3 84 267–269 MeOH C21H18N4O2 3,296; 1,675;
1,666
2.38 (s, 3H, CH3);
5.34 (s, 2H, CH2); 5.82 (s, 1H, H6);
6.35 (d, 1H, H3); 7.16 (d, 2H, ArH);
7.53 (d, 2H, ArH); 7.76 (d, 2H, ArH);
7.86 (d, 1H, H2); 7.93 (d, 2H, ArH);
10.30 (s, 1H, NH, exc.)
8 NHCONHC6H4-p-CF3 75 272–275 MeOH C21H19N5O2 3,330; 3,283;
1,665
2.38 (s, 3H, CH3);
5.30 (s, 2H, CH2); 5.81 (s, 1H, H6);
6.36 (d, 1H, H3); 6.97 (d, 2H, ArH);
7.09 (d, 2H, ArH); 7.27 (d, 2H, ArH);
7.43 (d, 2H, ArH); 7.86 (d, 2H, H2);
8.64 (s, 1H, NH, exc.); 8.72 (s, 1H, NH, exc.)
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Table S4. Analytical data of compounds 2a–i, 3a–c, 4a–c, and 5–8
No. Formula Calcd. % Found %
C H N C H N
2a C12H23N3 68.85 11.07 20.07 68.62 11.15 20.13
2b C13H25N3 69.91 11.28 18.81 69.80 11.40 18.64
2c C14H27N3 70.83 11.46 17.70 70.89 11.63 19.58
2d C21H41N3 75.16 12.32 12.52 75.06 12.28 12.37
2e C25H49N3 76.66 12.61 10.73 76.67 12.71 10.64
2f C13H25N3 69.91 11.28 18.81 69.90 11.40 18.70
2g C10H10N4O2 55.04 4.62 25.68 55.18 4.69 25.73
2h C17H15N5O4 57.79 4.28 19.82 57.91 4.33 19.95
2i C10H10N4O2 55.04 4.62 25.68 55.28 4.73 25.61
3a C16H25N3O 69.78 9.15 15.26 69.58 9.11 15.36
3b C17H27N3O 70.55 9.40 14.52 70.65 9.54 14.61
3c C18H29N3O 71.25 9.63 13.85 71.29 9.74 13.98
4a C16H25N3O 69.78 9.15 15.26 69.77 9.14 15.20
4b C17H27N3O 70.55 9.40 14.52 70.50 9.36 14.65
4c C18H29N3O 71.25 9.63 13.85 71.27 9.59 13.81
5 C14H12N4O3 59.15 4.25 19.71 59.23 4.38 19.84
6 C14H14N4O 66.13 5.55 22.03 66.26 5.60 21.98
7 C21H18N4O2 70.38 5.06 15.63 70.28 4.96 15.51
8 C21H19N5O2 67.55 5.13 18.76 67.52 5.10 18.61
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